Jul. 14 at 1:55 PM
$IKT RA Capital bought the entire block RA Capital is one of the most respected biotech hedge funds in the world (Peter Kolchinsky). They don't take 25 million shares of a sub-
$2 stock without deep diligence and high conviction. This is a smart-money endorsement, not a fire sale.
Single buyer, not market drip This wasn't a slow ATM bleed into the open market over weeks. It was a block sale to one institutional buyer. The dilution happened in a controlled way, not a death-by-a-thousand-cuts.
Fully funded through Phase 3 The company explicitly stated the capital funds operations through topline data readout in Part B of the IMPROVE-PAH Phase 3 trial. That removes the "will they run out of money?" overhang entirely. No more financing risk until the binary catalyst.
Phase 3 already enrolling First patient was enrolled in IMPROVE-PAH back in April 2026.
Inhibikase raises
$50 million through stock sale to RA Capital
More details about Inhibikase raises
$50 million through stock sale to RA
